Plasma Fractionation Market to grow by USD 10.00 billion, 5.81% YOY growth expected in 2024, North America to Experience Maximum Growth - Technavio

The growing prevalence of respiratory diseases drives the growth, with the growing elderly population and related disorders as a major trend and ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., and CSL Ltd. are some of the major players.

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- The

Plasma Fractionation Market report has been added to Technavio's offering. The plasma fractionation market is estimated to grow by

USD 10.00 billion during 2023-2028, growing at a

CAGR of 6.09%.

North America will contribute

34% to the growth of the global market during the forecast period. In North America, the Plasma Fractionation Market is experiencing significant growth, which is driven by established plasma collection centers and a culture of voluntary plasma donation in the US, Canada, and Mexico. The region benefits from a consistent plasma supply, supported by government and non-governmental organizations. The growth is further propelled by the expansion of hospital services and an increasing demand for plasma fractionation in medical care procedures involving blood transfusions.

For Comprehensive details on the market size of the historical period(2018 to 2022) and forecast period (2024-2028) - View a FREE Sample Report

Continue Reading

Preview

来源: PRNewswire

Technavio has announced its latest market research report titled Global Plasma Fractionation Market 2024-2028

What is one of the major drivers for the growth during the forecast period?

The

rising prevalence of respiratory diseases, particularly Alpha-1 Antitrypsin Deficiency (AATD)Alpha-1 Antitrypsin Deficiency (AATD), is a key driver for the Plasma Fractionation Market. Plasma-derived products derived from fractionation find applications in various therapeutic indications beyond respiratory diseases, contributing to market growth. Increased awareness, improved diagnostics, and early identification of respiratory diseases prompt the demand for plasma-derived products, fostering market expansion.

What are the factors challenging the growth during the forecast period?

Although factors such as the growing elderly population and related disorders fuel the growth, the

stringent government regulations regarding the safety of plasma-derived products may hamper the growth, says a senior analyst at Technavio.

Technavio has identified key trends, drivers, and challenges in the market, which will help clients improve their strategies to stay ahead of their competitors. - View a FREE Sample Report

What are some major companies in the industry?

The plasma fractionation market is fragmented; the vendors are competing with competitors and are trying to get greater market share. The market is growing, and the chances of new entrants cannot be overlooked. The major vendors have well-established economies of scale and market presence and generally rely on positioning technological advances, and the price of the products -

The report provides a full list of key vendors, their strategies, and the latest developments. Buy Now

The plasma fractionation market report includes information on the product launches, sustainability, and prospects of leading vendors including ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., CSL Ltd., Emergent BioSolutions Inc., GC Biopharma Corp., Grifols SA,  Hemarus Plasma, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A, LFB SA, Merck KGaA, Mitsubishi Chemical Group Corp., Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions Netherlands BV, Sanquin, SK Inc., Takeda Pharmaceutical Co. Ltd., and Virchow Laboratories Ltd.

What are some of the performance indicators?

The report includes competitive analysis, a proprietary tool to analyze and evaluate the position of companies based on their industry position score and market performance score. The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others.

Which segment is significant during the forecast period?

By Product, the immunoglobulins segment will have the largest share of the market during the forecast period.

What are the technological trends shaping the industry?

The Plasma Fractionation Market involves the separation of blood plasma into essential components like Albumin, Immunoglobulins, and Coagulation Factors. Plasma-derived therapeutics, including Intravenous Immunoglobulin (IVIG), Factor VIII, and Factor IX, address conditions like Hemophilia and Immunodeficiency Disorders. Market trends emphasize efficient Plasma Collection, rigorous Purification Processes, and Pathogen Inactivation for regulatory compliance, with companies driving innovation in the field.

Related Reports:

The

plasma lamp market size is estimated to grow at a CAGR of 4.8% between 2023 and 2028. The market size is forecast to increase by USD 143.06 million.

The

plasma cutting machine market size is estimated to grow at a CAGR of 5.62% between 2023 and 2028. The market size is forecast to increase by USD 539.92 million.

ToC

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Segmentation by Product

7 Segmentation by Application

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Vendor Landscape

12 Vendor Analysis

13 Appendix

About US

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com

SOURCE Technavio

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。